Mexico

mexico-city-cathedral-small.jpgMexico’s pharmaceutical industry generates revenues of around $11 billion, making it the 11th largest pharma market in the world. In Latin America, Mexico comes in second after Brazil, which leads the region with $16 billion.

In Mexico, the sector has been traditionally stable with large profit margins, but it is currently undergoing a rapid transformation. Companies are starting to adapt their strategies to the new conditions in different ways. The changes cut across a number of areas including product development, competition, distribution, and regulation.

Generics lead the way

The adoption of generics means that more than 60% of all units sold in Mexico are generic. In the private market, their growth has been exponential for the last few years. While new regulation has helped eliminate products that did not fulfill regulatory therapeutic efficiency, there are patients and doctors who are still wary of these products, which has allowed patented medicines to extend their life cycles.

In 2008, the Mexican government eliminated the mandatory manufacturing requirement allowing new companies to establish operations in the country, including Takeda, Daiichi Ranbaxy and Astellas. Other Mexican players who bet on niche OTC products, such as Genomma Lab, have experienced substantial growth. Given this heightened competition, local and global players need to modify their strategies and reposition themselves in the market.

Source: Russell Reynolds Associates.

1 to 10 of 13 results

Mexico News

  • EASD 2014: Novo Nordisk updates on Ryzodeg, Tresiba and Xultophy

    EASD 2014: Novo Nordisk updates on Ryzodeg, Tresiba and Xultophy

    19-09-2014

    The global burden of diabetes is growing fast with an astonishing 10% of global healthcare expense spent on diabetes. Danish diabetes care giant Novo Nordisk is leading the fight against this growing burden, with a number of revolutionary treatments against the disease. The company presented highlights from its diabetes portfolio at a briefing at the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria, this week.

  • Mexico first country to launch Novo Nordisk’s Ryzodeg

    Mexico first country to launch Novo Nordisk’s Ryzodeg

    01-09-2014

    Danish diabetes care giant Novo Nordisk today announced that Mexico has become the first country in the world to launch Ryzodeg, making the drug available for people with type 2 diabetes.

  • Asthma agents currently face a suboptimal coverage environment in Brazil and Mexico

    Asthma agents currently face a suboptimal coverage environment in Brazil and Mexico

    21-08-2014

    The asthma market in Brazil and Mexico currently faces severe coverage restrictions and, as the treatment armamentarium expands, competitiveness will further intensify.

  • Mexico’s health care market to reach almost $28 billion by 2020

    Mexico’s health care market to reach almost $28 billion by 2020

    07-08-2014

    Mexico’s pharmaceutical and medical devices industries will be worth around $22.5 billion and $5.4 billion by 2020, respectively, totaling an overall health care market value of $27.9 billion.

  • Brazil and Mexico physicians’ preferences on anticoagulants

    25-07-2014

    Novel oral anticoagulants (NOACs) such as Bayer’s Xarelto (rivaroxaban), Boehringer Ingelheim’s Pradaxa (dabigatran etexilate) and Bristol-Myers Squibb/Pfizer’s Eliquis (apixaban) are preferred treatments for venous thromboembolism (VTE), atrial fibrillation (AF) and acute coronary syndrome (ACS) among physicians and payers in Brazil and Mexico.

  • Fast growth forecast for dengue vaccine market

    Fast growth forecast for dengue vaccine market

    18-07-2014

    Among the five major pharmaceutical markets (5MM: Brazil, India, Mexico, Singapore and Thailand), Brazil and Mexico are projected to be the leading contributors to the dengue vaccine marketplace, as it expands rapidly from an estimated $70 million in 2015 to $400 million by 2020, at a compound annual growth rate (CAGR) of 42%.

  • moksha8 to commercialize BIAL’s eslicarbazepine in Brazil and Mexico

    moksha8 to commercialize BIAL’s eslicarbazepine in Brazil and Mexico

    15-07-2014

    Portuguese drugmaker BIAL and Brazil-based moksha8 have entered an exclusive license for the commercialization of eslicarbazepine acetate (Zebinix/Exalief) in Brazil and Mexico for the treatment of epilepsy.

  • Targeted therapies must show cost effectiveness to compete with biosimilars in Brazil and Mexico

    Targeted therapies must show cost effectiveness to compete with biosimilars in Brazil and Mexico

    10-06-2014

    Certain targeted therapies enjoy extensive but incomplete coverage in Brazil and Mexico through complex mechanisms, according to research by Decision Resources Group.

  • Generic drugs will be a key element of Mexico's health care modernization; report

    16-05-2014

    Although Mexico has made great efforts to improve its regulatory framework and create a more hospitable business environment to entice pharmaceutical companies, Business Monitor identifies that it is still hard for multinationals to fully materialize their commercial benefit due to the significant market share of generic drugs.

  • Endo to buy Mexican specialty pharma company Somar

    29-04-2014

    USA-based Endo International as entered into a definitive agreement to acquire Grupo Farmaceutico Somar, a leading privately-owned specialty pharmaceuticals company based in Mexico City, Mexico, for an undisclosed cash consideration.

1 to 10 of 13 results

Parexel

Parexel

Back to top